TOVX Valuation

Theriva Biologics Inc

Add to Watchlist

Advanced Chart

0.500

+0.006(1.215%)1D

Overview
Forecast
Valuation
Earnings

TOVX Relative Valuation

TOVX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TOVX is overvalued; if below, it's undervalued.

Historical Valuation

Theriva Biologics Inc (TOVX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.25. The fair price of Theriva Biologics Inc (TOVX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.50

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.09

P/B

Median3y

0.20

Median5y

0.06

-375.76

FCF Yield

Median3y

-292.85

Median5y

-197.61

Competitors Valuation Multiple

The average P/S ratio for TOVX's competitors is 16.70, providing a benchmark for relative valuation. Theriva Biologics Inc Corp (TOVX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TOVX.A

Theriva Biologics Inc

Loss

Average P/S: 16.70

4.48M